epidemiolog
associ
specif
pathogen
alway
must
consid
eg
coccidioidomyc
spp
southwestern
unit
state
sever
acut
respiratori
syndrom
sar
travel
part
asia
although
author
propos
syndrom
approach
therapi
count
predict
caus
base
present
clinic
manifest
data
indic
present
clinic
featur
specif
enough
reliabl
predict
caus
cap
studi
shown
atyp
pathogen
chlamydophila
pneumonia
legionella
spp
virus
may
serv
copathogen
tradit
bacteria
make
difficult
know
appropri
treat
bacteri
pathogen
select
specif
antimicrobi
regimen
empir
therapi
base
larg
number
principl
includ
predict
like
pathogen
aid
knowledg
commonli
encount
pathogen
geograph
area
appreci
usual
suscept
pattern
presenc
medic
comorbid
may
influenc
pathogen
increas
likelihood
drugresist
streptococcu
pneumonia
drsp
potenti
risk
factor
clinic
failur
box
factor
consider
specif
antimicrobi
includ
spectrum
activ
potenti
induc
resist
pharmacokinet
pharmacodynam
efficaci
safeti
profil
clinic
trial
show
proven
efficaci
cost
although
cap
may
caus
mani
possibl
pathogen
limit
number
common
pathogen
respons
case
emerg
newli
recogn
pathogen
novel
coronaviru
associ
sar
continu
increas
challeng
appropri
manag
cap
box
principl
empir
antimicrobi
therapi
communityacquir
pneumonia
tabl
list
common
pathogen
associ
cap
base
collect
result
recent
studi
base
sever
ill
judg
site
care
outpati
versu
inpati
collect
pneumonia
frequent
isol
pathogen
rel
pathogen
mycoplasma
pneumonia
c
pneumonia
haemophilu
influenza
legionella
pneumophila
respiratori
virus
also
common
atyp
pathogen
except
l
pneumophila
identifi
often
clinic
practic
howev
specif
rapid
standard
test
detect
although
influenza
remain
predomin
viral
caus
cap
adult
recogn
pathogen
includ
respiratori
syncyti
viru
parainfluenza
viru
less
commonli
adenoviru
metapneumoviru
herpesviru
varicella
sarsassoci
coronaviru
measl
studi
nonimmunocompromis
adult
admit
cap
patient
evid
viral
caus
patient
respiratori
viru
pathogen
identifi
staphylococcu
aureu
enterobacteriacea
pseudomona
aeruginosa
pathogen
found
select
group
patient
influenza
previous
taken
antimicrobi
drug
pulmonari
comorbid
identifi
risk
factor
gramneg
bacteria
includ
recent
antibiot
therapi
pulmonari
comorbid
recent
hospit
latter
two
risk
factor
also
predict
p
aeruginosa
like
gramneg
pathogen
pneumonia
caus
communityassoci
methicillinresist
aureu
camrsa
observ
type
pneumonia
uncommon
import
recogn
potenti
seriou
consequ
camrsa
strain
seem
distinct
hospitalacquir
strain
epidemiolog
genotyp
phenotyp
perspect
tend
less
resist
antimicrobi
drug
hospitalacquir
mrsa
strain
almost
alway
contain
noveltyp
iv
staphylococc
cassett
chromosom
sccmec
gene
mani
strain
found
contain
gene
pantonvalentin
leukocidin
patient
admit
icu
sever
cap
predomin
pathogen
pneumococcu
atyp
pathogen
h
influenza
enter
gramneg
bacteria
aureu
care
done
bronchoscop
studi
nursinghom
patient
sever
cap
set
suspect
aspir
identifi
enter
gramneg
bacteria
predomin
pathogen
found
anaerob
uncommon
often
identifi
bacteria
requir
specif
therapi
atyp
pathogen
respons
sever
cap
may
vari
time
account
collect
approxim
pneumonia
episod
domin
pathogen
pathogen
aspect
legionella
spp
although
object
confirm
often
difficult
multipl
organ
infect
patient
concurr
sequenti
may
caus
cap
influenza
c
pneumonia
infect
might
follow
secondari
infect
pneumonia
one
studi
patient
hospit
serolog
diagnos
c
pneumonia
pneumonia
patient
infect
pathogen
common
pneumococcu
import
treat
multipl
infect
organ
establish
howev
identif
one
pathogen
preclud
evalu
caus
particularli
case
cap
respond
therapi
emerg
resist
respiratori
pathogen
particularli
strain
drsp
influenc
initi
empir
manag
cap
clinic
relev
drsp
pneumonia
imprecis
subject
sever
review
wellcontrol
studi
examin
impact
vitro
resist
clinic
outcom
cap
publish
studi
limit
small
sampl
size
bias
inher
observ
design
rel
infrequ
isol
show
highlevel
resist
among
clinic
isol
studi
suggest
current
level
blactam
resist
gener
result
treatment
failur
patient
cap
appropri
agent
ie
amoxicillin
ceftriaxon
cefotaxim
dose
use
avail
data
suggest
clinic
relev
level
penicillin
resist
minim
inhibitori
concentr
mic
least
mgl
one
report
suggest
cefuroxim
use
treat
pneumococc
bacteremia
organ
resist
vitro
outcom
may
wors
therapi
use
discord
therapi
impact
mortal
data
suggest
resist
macrolid
respiratori
fluoroquinolon
levofloxacin
may
result
clinic
failur
howev
interpret
limit
rel
small
number
patient
report
risk
factor
penicillinresist
pneumonia
identifi
age
year
year
blactam
therapi
within
previou
month
alcohol
medic
comorbid
immunosuppress
ill
therapi
exposur
child
day
care
center
although
rel
predict
valu
risk
factor
unclear
treatment
antimicrobi
drug
like
signific
factor
sever
set
data
shown
recent
therapi
blactam
macrolid
quinolon
risk
factor
pneumococc
resist
class
antibiot
repeat
cours
antibiot
class
risk
factor
pneumococc
resist
agent
one
studi
found
presenc
pneumococc
bacteremia
use
blactam
macrolid
within
past
month
increas
likelihood
infect
penicillinresist
organ
studi
recent
use
quinolon
predict
increas
likelihood
penicillin
resist
studi
shown
repeat
use
quinolon
predict
increas
risk
quinoloneresist
pneumococci
remain
uncertain
risk
appli
equal
quinolon
concern
less
activ
pneumococc
agent
levofloxacin
activ
agent
moxifloxacin
gemifloxacin
numer
guidelin
recommend
antimicrobi
manag
cap
publish
specif
recommend
empir
therapi
cap
includ
sever
publish
guidelin
north
america
unit
kingdom
japan
list
tabl
combin
consensu
guidelin
american
thorac
societi
at
infecti
diseas
societi
america
prepar
niederman
file
person
commun
north
american
na
guidelin
variabl
recommend
macrolid
doxycyclin
antipneumococc
fluoroquinolon
eg
gatifloxacin
gemifloxacin
levofloxacin
moxifloxacin
combin
blactam
plu
macrolid
treatment
option
patient
mildli
ill
treat
outpati
gener
na
guidelin
recommend
macrolid
firstlin
treatment
outpati
comorbid
risk
factor
drsp
rational
macrolid
provid
effect
therapi
common
bacteri
pathogen
patient
ie
primarili
pneumonia
atyp
organ
especi
pneumonia
c
pneumonia
common
outpati
posit
macrolid
promin
firstlin
agent
na
guidelin
partial
base
presumpt
new
macrolid
azithromycin
clarithromycin
effect
mrsp
strain
lowerlevel
resist
result
increas
drug
efflux
result
mic
often
less
lgml
data
indic
mefmedi
resist
becom
associ
higher
mic
median
lg
ml
median
lgml
reason
consid
altern
therapi
ie
respiratori
fluoroquinolon
ketolid
highdos
amoxicillin
gd
adult
plu
macrolid
risk
factor
drsp
present
contrast
primari
agent
recommend
british
thorac
societi
bt
guidelin
blactam
primarili
penicillin
rather
macrolid
rational
agent
effect
pneumonia
given
high
dose
even
effect
strain
decreas
sensit
penicillin
macrolid
resist
europ
ermmedi
highlevel
resist
macrolid
regard
optim
firstlin
empir
agent
treat
pathogen
pneumonia
infect
consid
like
british
guidelin
place
less
signific
need
treat
empir
patient
infect
atyp
pathogen
ambulatori
mild
diseas
guidelin
suggest
pneumonia
exhibit
epidem
period
everi
year
larg
affect
younger
patient
polici
initi
empir
therapi
aim
alway
cover
pathogen
unnecessari
two
approach
repres
na
bt
guidelin
differ
primarili
greater
emphasi
north
america
routin
treat
atyp
pathogen
fact
mrsp
europ
higherlevel
resist
north
america
studi
need
answer
question
regard
need
routin
treat
atyp
pathogen
japanes
guidelin
advoc
initi
therapi
base
syndrom
approach
ie
macrolid
tetracyclin
treatment
like
atyp
pneumonia
penicillintyp
therapi
bacteri
pneumonia
na
guidelin
recommend
treatment
blactam
plu
macrolid
monotherapi
fluoroquinolon
patient
admit
gener
ward
rational
partli
result
studi
show
regimen
associ
signific
reduct
mortal
rate
compar
mortal
rate
associ
cephalosporin
treatment
alon
although
limit
retrospect
design
studi
found
use
macrolid
part
initi
combin
therapi
usual
cephalosporin
agent
fluoroquinolon
monotherapi
patient
requir
hospit
seem
associ
decreas
mortal
rate
shorter
hospit
stay
compar
use
cephalosporin
alon
specif
caus
infect
determin
studi
howev
ad
coverag
atyp
pathogen
partli
may
explain
observ
recommend
bt
guidelin
similar
na
guidelin
japanes
guidelin
stratifi
patient
base
age
presenc
underli
ill
use
inject
use
fluoroquinolon
recommend
younger
patient
less
seriou
diseas
combin
regimen
recommend
patient
patient
sever
cap
requir
icu
admiss
guidelin
recommend
comprehens
antimicrobi
therapi
cover
infect
pneumonia
includ
drsp
legionella
spp
potenti
gramneg
bacilli
includ
pseudomona
spp
selectedcas
author
recommend
empir
therapi
cap
outpati
patient
admit
gener
ward
patient
requir
icu
admiss
list
box
therapeut
regimen
consid
effect
patient
ie
patient
like
one
common
caus
list
tabl
author
recogn
signific
minor
patient
epidemiolog
risk
factor
pathogen
antimicrobi
therapi
warrant
patient
epidemiolog
factor
associ
pathogen
list
tabl
patient
mild
ambulatori
pneumonia
signific
medic
comorbid
ie
diabet
chronic
inflammatori
lung
diseas
liver
renal
insuffici
malign
congest
heart
failur
recent
treat
antimicrobi
agent
treatment
extendedspectrum
macrolid
clarithromycin
azithromycin
doxycylin
appropri
recent
studi
common
pathogen
patient
pneumonia
pneumonia
c
pneumonia
h
influenza
mycoplasma
spp
commonli
found
patient
younger
year
without
signific
comorbid
condit
abnorm
vital
sign
pneumonia
common
pathogen
older
patient
patient
signific
underli
diseas
h
influenza
found
patient
mostli
patient
comorbid
cigarett
smoke
import
therapi
mycoplasma
spp
chlamydia
spp
infect
mild
cap
subject
conjectur
mani
infect
selflimit
studi
indic
treatment
mild
pneumonia
cap
reduc
morbid
pneumonia
shorten
durat
symptom
macrolid
constitut
longstand
class
antimicrobi
treatment
outpati
cap
unit
state
class
includ
erythromycintyp
agent
includ
dirithromycin
extendedspectrum
macrolid
clarithromycin
azalid
azithromycin
agent
signific
role
manag
cap
activ
pneumonia
atyp
pathogen
although
erythromycin
least
expens
drug
use
often
gastrointestin
intoler
lack
activ
h
influenza
light
activ
h
influenza
advanc
macrolideandazalid
combin
use
consid
treatment
outpati
comorbid
chronic
obstruct
pulmonari
diseas
numer
random
clinic
trial
document
efficaci
advanc
macrolideandazalid
combin
monotherapi
azithromycin
clarithromycin
outpati
despit
report
clinic
failur
macrolid
treatment
outpati
pneumococc
pneumonia
number
rel
small
light
larg
number
patient
treat
patient
hospit
treat
blactam
macrolid
gener
surviv
patient
risk
factor
monotherapi
macrolid
recommend
guidelin
patient
without
signific
risk
drsp
gramneg
bacilli
monotherapi
macrolid
still
consid
appropri
doxycyclin
includ
costeffect
altern
part
base
vitro
data
indic
drug
least
effect
erythromycin
treat
pneumococc
isol
howev
littl
clinic
trial
data
avail
fluoroquinolon
treatment
ambulatori
cap
without
comorbid
condit
recent
antimicrobi
use
discourag
fear
widespread
use
may
lead
develop
fluoroquinolon
resist
among
respiratori
pathogen
colon
pathogen
studi
outpati
shown
mani
quinolon
recipi
could
receiv
agent
prefer
firstlin
therapi
quinolon
recipi
may
requir
antibiot
treatment
dose
durat
employ
often
incorrect
type
usag
pattern
rais
concern
promot
rapid
develop
antibiot
resist
quinolon
class
antibiot
likelihood
develop
drsp
enter
gramneg
bacteria
increas
patient
comorbid
recent
antimicrobi
therapi
patient
recommend
empir
therapeut
option
includ
respiratori
fluoroquinolon
gatifloxacin
gemifloxacin
levofloxacin
moxifloxacin
ketolid
alon
ie
telithromycin
enter
gramneg
bacteria
concern
combin
therapi
betalactam
plu
macrolid
doxycyclin
altern
effect
box
empir
select
antimicrobi
agent
treat
patient
communityacquir
pneumonia
outpati
previous
healthi
use
antimicrobi
drug
within
previou
month
extendedspectrum
macrolid
clarithromycin
azithromycin
doxycylin
b
presenc
comorbid
ie
diabet
liver
diseas
renal
insuffici
malign
chronic
inflammatori
lung
diseas
congest
heart
diseas
use
antimicrobi
drug
within
previou
month
depend
class
antibiot
recent
given
altern
option
differ
class
select
respiratori
fluoroquinolon
gatifloxacin
levofloxacin
moxifloxacin
gemifloxacin
telithromycin
risk
enter
gramneg
organ
blactam
highdos
amoxicillin
eg
g
three
time
daili
g
amoxicillinclav
twice
daili
prefer
altern
cefpodoxim
cefuroxim
cefprozil
cefdinir
plu
macrolid
altern
doxycyclin
ceftriaxon
intramuscular
intraven
plu
macrolid
doxycylin
inpati
gener
ward
respiratori
fq
blactam
prefer
agent
includ
cefotaxim
ceftriaxon
ampicillinsulbactam
consid
ertapenem
select
patient
plu
macrolid
doxycyclin
care
select
patient
risk
factor
drsp
gramneg
organ
use
monotherapi
azithromycin
consid
consid
risk
factor
pathogen
see
tabl
pseudomona
consider
blactam
cefotaxim
ceftriaxon
ampicillinsulbactam
ertapenem
plu
azithromycin
respiratori
fq
patient
penicillin
allergi
respiratori
fluoroquinolon
without
clindamycin
pseudomona
consider
sever
structur
lung
diseas
bronchiectasi
chronic
obstruct
pulmonari
diseas
repeat
antimicrobi
steroid
use
pneumonia
infect
regimen
may
appropri
use
patient
without
comorbid
recent
antimicrobi
live
place
high
preval
pneumonia
infect
highlevel
macrolid
resist
base
pharmacodynam
principl
highdosag
amoxicillin
g
amoxicillin
three
time
daili
g
amoxicillin
potassium
clavulan
two
time
daili
effect
case
pneumonia
infect
amoxicillin
prefer
blactam
patient
without
type
penicillin
allergi
select
cephalosporin
cefpodoxim
cefuroxim
use
altern
drug
less
activ
vitro
highdos
amoxicillin
telithromycin
first
ketolid
approv
treatment
mildtomoder
cap
use
drsp
risk
agent
shown
efficaci
patient
bacteremia
higher
pneumonia
sever
ill
psi
score
vitro
telithromycin
activ
pneumonia
resist
antimicrobi
includ
penicillin
macrolid
fluoroquinolon
data
sever
control
doubleblind
cap
trial
suggest
telithromycin
effect
compar
includ
amoxicillin
clarithromycin
trovafloxacin
avail
inform
suggest
telithromycin
avail
oral
agent
import
role
treatment
cap
caus
pneumonia
common
atyp
pathogen
efficaci
agent
h
influenza
infect
similar
new
macrolid
data
involv
patient
infect
need
anoth
possibl
option
empir
treatment
outpati
modifi
factor
depend
set
use
parenter
intramuscular
intraven
ceftriaxon
given
oral
macrolid
ketolid
doxycylin
outpati
servic
increasingli
avail
antipneumococc
antipseudomon
blactam
piperacillin
cefepim
imipenem
meropenem
plu
ciprofloxacin
levofloxacin
mg
antipneumococc
antipseudomon
blactam
plu
aminoglycosid
intraven
macrolid
intraven
antipneumococc
quinolon
patient
penicillin
allergi
aztreonam
plu
levofloxacin
mg
aztreonam
plu
moxifloxacin
gatifloxacin
without
aminoglycosid
consid
risk
factor
pathogen
see
tabl
consid
regimen
list
b
patient
region
high
rate
highlevel
macrolideresist
pneumonia
parenter
antimicrobi
therapi
may
appropri
select
patient
mild
diseas
recommend
regimen
inpati
gener
ward
blactam
plu
macrolid
altern
doxycylin
ketolid
monotherapi
fluoroquinolon
consid
effect
treat
pneumonia
infect
numer
studi
shown
empir
treatment
either
regimen
associ
signific
reduct
mortal
rate
length
hospit
stay
compar
treatment
cephalosporin
alon
prefer
blactam
effect
treat
pneumonia
infect
overli
broad
spectrum
howev
treatment
antipneumococc
antipseudomon
agent
eg
cefepim
piperacillin
tazobactam
appropri
resist
pathogen
involv
pneumonia
coexist
infect
januari
nation
committe
clinic
laboratori
standard
nccl
increas
mic
breakpoint
cefotaxim
ceftriaxon
treatment
nonmening
pneumonia
infect
new
breakpoint
acknowledg
nonmening
infect
caus
strain
formerli
consid
intermedi
suscept
even
strain
regard
resist
treat
success
usual
dose
blactam
ertapenem
includ
blactam
option
light
two
random
doubleblind
studi
show
treatment
equival
result
compar
result
ceftriaxon
therapi
drug
also
excel
activ
anaerob
organ
enterobacteriacea
includ
produc
extendedspectrum
blactamas
produc
p
aeruginosa
may
use
patient
risk
pathogen
particularli
elderli
patient
admit
nurs
home
patient
recent
receiv
antibiot
therapi
clinic
experi
ertapenem
limit
howev
doxycyclin
use
altern
macrolid
base
minimaltomoder
experi
treatment
legionella
infect
monotherapi
azithromycin
consid
select
patient
nonsever
diseas
may
admit
reason
cap
risk
drsp
gramneg
pathogen
data
two
random
doubleblind
studi
adult
hospit
cap
demonstr
parenter
azithromycin
monotherapi
effect
intraven
cefuroxim
therapi
without
intraven
erythromycin
azalid
monotherapi
regimen
greater
toler
feldman
et
al
review
record
patient
cap
admit
veteran
affair
facil
decemb
juli
compar
outcom
patient
receiv
azithromycin
monotherapi
outcom
patient
receiv
atsrecommend
antibiot
nonatsrecommend
antibiot
outcom
includ
time
stabil
length
stay
lo
mortal
adjust
sever
ill
mean
psi
score
azithromycin
group
versu
at
group
p
process
care
patient
requir
icu
manag
exclud
mortal
readmiss
rate
similar
among
group
mean
lo
shorter
azithromycin
group
none
patient
erythromycinresist
pneumonia
infect
die
transfer
icu
includ
six
patient
receiv
azithromycin
retrospect
analysi
impact
initi
antibiot
choic
mortal
rate
patient
admit
hospit
cap
brown
et
al
observ
patient
receiv
monotherapi
macrolid
lowest
mortal
rate
least
ill
patient
younger
like
lowrisk
group
although
admit
patient
initi
treat
intraven
regimen
mani
patient
particularli
without
risk
factor
sever
pneumonia
receiv
oral
therapi
especi
highli
bioavail
agent
quinolon
intraven
blactam
combin
coverag
atyp
pathogen
addit
macrolid
doxycyclin
ketolid
achiev
oral
therapi
care
select
patient
without
sever
pneumonia
risk
factor
patient
intens
care
unit
icu
patient
like
ill
risk
factor
resist
pathogen
review
nine
studi
includ
patient
cap
admit
icu
common
pathogen
order
frequenc
pneumonia
legionella
spp
h
influenza
enterobacteriacea
aureu
pseudomona
spp
patient
without
risk
pseudomona
infect
coverag
pneumonia
legionella
speci
ensur
combin
potent
antipneumococc
blactam
advanc
macrolid
respiratori
fluoroquinolon
provid
effect
spectrum
patient
role
monotherapi
respiratori
fluoroquinolon
yet
establish
sever
cap
patient
pneumococc
mening
efficaci
quinolon
monotherapi
uncertain
risk
factor
pseudomona
infect
present
infect
site
coexist
pseudomona
spp
resist
pathogen
consider
therapi
includ
agent
effect
pneumococcu
pseudomona
spp
legionella
spp
piperacillintazobactam
imipenem
meropenem
cefepim
prefer
blactam
concern
unusu
pathogen
p
aeruginosa
gramneg
bacteria
patient
good
clinic
respons
initi
therapi
coexist
medic
problem
stabil
patient
eat
drink
consider
given
switch
intraven
oral
antibiot
therapi
ramirez
et
al
defin
set
criteria
earli
switch
intraven
oral
therapi
includ
improv
cough
dyspnea
fever
less
c
least
hour
normal
white
blood
cell
count
oral
intak
adequ
intestin
function
criteria
discuss
ramirez
anoth
articl
issu
sever
patient
clinician
awar
potenti
pathogen
separ
addit
common
organ
empir
therapi
box
direct
among
pathogen
respiratori
virus
although
prospect
control
studi
antivir
treatment
viral
pneumonia
report
adult
antivir
therapi
warrant
influenza
varicella
herpesviru
virus
select
circumst
tabl
ambulatori
adult
influenza
earli
treatment
inhal
zanamivir
oral
oseltamivir
seem
reduc
likelihood
lower
respiratori
tract
complic
use
influenza
antivir
medic
seem
reduc
likelihood
respiratori
tract
complic
reflect
reduc
rate
antibacteri
agent
use
ambulatori
patient
influenza
one
retrospect
studi
hospit
adult
influenza
minor
radiograph
document
pneumonia
obviou
benefit
amantadin
treatment
found
howev
patient
often
recover
viru
hospit
median
durat
day
antivir
treatment
seem
reason
broad
influenza
spectrum
low
risk
resist
emerg
lack
bronchospasm
risk
oseltamivir
appropri
treatment
choic
hospit
patient
antimicrobi
therapi
infect
pathogen
associ
epidemiolog
condit
list
tabl
clinician
consid
import
epidemiolog
associ
choos
agent
consid
need
provid
effect
therapi
core
group
pathogen
eg
pneumonia
atyp
pathogen
caus
infect
identifi
reliabl
microbiolog
method
expert
recommend
antimicrobi
therapi
direct
pathogen
possibl
atyp
pathogen
coinfect
howev
author
question
approach
light
recent
data
treatment
option
may
simplifi
etiolog
agent
establish
strongli
suspect
see
tabl
diagnost
procedur
provid
identif
specif
caus
within
hour
still
use
guid
continu
therapi
appropri
cultur
reveal
isol
penicillinsuscept
pneumonia
therapi
specifi
select
narrowspectrum
agent
penicillin
amoxicillin
hope
approach
reduc
select
pressur
resist
inform
often
avail
consider
patient
switch
parenter
oral
therapi
may
use
direct
specif
antimicrobi
choic
sever
studi
suggest
dual
therapi
includ
empir
macrolid
reduc
mortal
rate
associ
bacterem
pneumococc
pneumonia
uncertain
impact
find
principl
narrow
regimen
effect
monotherapi
result
suscept
known
result
studi
led
suggest
observ
might
result
presenc
unknown
coinfect
atyp
pathogen
altern
explan
immunomodulatori
effect
macrolid
studi
signific
design
limit
prospect
random
evalu
effect
initi
empir
therapi
result
blood
cultur
known
examin
effect
pathogenspecif
therapi
result
blood
cultur
avail
need
provid
pathogenspecif
therapi
anaerob
pathogen
patient
suspect
aspir
pneumonia
uncertain
studi
shown
set
patient
improv
without
specif
therapi
direct
pathogen
mrsa
becom
common
cap
effect
therapi
need
defin
camrsa
strain
reportedli
associ
skin
infect
also
associ
pneumonia
primarili
children
although
author
observ
case
adult
winter
gener
strain
suscept
vitro
nonblactam
antimicrobi
drug
hospitalacquir
strain
often
suscept
vitro
trimethoprim
sulfamethoxazol
fluoroquinolon
although
pocket
fluoroquinoloneresist
strain
exist
often
suscept
clindamycin
emerg
resist
therapi
report
especi
erythromycinresist
strain
insuffici
data
use
agent
treat
adult
camrsa
pneumonia
data
becom
avail
author
recommend
vancomycin
linezolid
initi
therapi
patient
patient
cap
receiv
treatment
least
day
wellcontrol
studi
evalu
optim
durat
therapi
patient
hospit
durat
difficult
defin
uniform
fashion
antibiot
administ
short
time
long
halflif
respiratori
site
infect
eg
azithromycin
patient
becom
clinic
stabl
within
day
longer
durat
therapi
rare
necessari
howev
patient
persist
clinic
instabl
often
readmit
hospit
may
candid
shortterm
therapi
shortterm
therapi
may
optim
patient
bacterem
aureu
pneumonia
risk
associ
endocard
deepseat
infect
patient
meningitiscompl
pneumonia
patient
p
aeruginosa
pneumonia
often
necrot
pneumonia
patient
infect
caus
less
common
pathogen
one
studi
therapi
nosocomi
pneumonia
p
aeruginosa
led
relaps
commonli
therapi
studi
defin
durat
therapi
focus
patient
receiv
accur
empir
therapi
data
exist
well
defin
durat
treatment
patient
initi
receiv
ineffect
therapi
regimen
trial
antibiot
therapi
cap
azithromycin
use
day
monotherapi
admit
patient
intraven
azithromycin
initi
day
treatment
option
chang
oral
treatment
complet
cours
day
oral
therapi
outpati
report
use
onedos
therapi
patient
atyp
pathogen
infect
ketolid
telithromycin
use
day
treat
outpati
includ
patient
pneumococc
bacteremia
psi
class
least
iii
antipneumococc
quinolon
use
day
inpati
outpati
patient
good
clinic
respons
within
day
two
studi
quinolon
shown
use
quinolon
dose
result
high
antipneumococc
activ
lead
rapid
clinic
respons
one
studi
recipi
levofloxacin
recipi
levofloxacin
becam
afebril
day
versu
p
studi
dose
success
day
therapi
anoth
studi
patient
receiv
mg
moxifloxacin
becam
afebril
day
rate
higher
compar
agent
studi
patient
switch
oral
therapi
day
base
avail
data
author
believ
patient
cap
treat
minimum
day
therapi
stop
patient
afebril
hour
one
clinic
instabl
longer
durat
therapi
may
need
initi
therapi
activ
identifi
etiolog
pathogen
longer
durat
therapi
need
extrapulmonari
infect
mening
endocard
patient
document
aureu
bacteremia
p
aeruginosa
pneumonia
infect
caus
sever
less
common
pathogen
eg
burkholderia
pseudomallei
fungu
may
need
longer
durat
therapi
